Tommaso Fisco

Tommaso Fisco

Auto-generated profile, based on publicly available information

Tommaso Fisco

Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2016 in Oncotarget
Verified
Journal Article
Open access
SPSabina Pucci
Sabina Pucci
MZMaria Josè Zonetti
Maria Josè Zonetti
TFTommaso Fisco
Tommaso Fisco
CPChiara Polidoro
Chiara Polidoro
Gianfranco BocchinfusoGianfranco Bocchinfuso
Gianfranco Bocchinfuso
PMPaola Mazzarelli
Paola Mazzarelli
Carnitine palmitoyl transferase-1A (CPT1A): a new tumor specific target in human breast cancer Carnitine palmitoyl transferase-1A (CPT1A): a new tumor specific target in human breast cancer

13 February 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AEAbdellatif Essabbani
Abdellatif Essabbani
LGLuis Garcia
Luis Garcia
MZMaria Josè Zonetti
Maria Josè Zonetti
TFTommaso Fisco
Tommaso Fisco
SPSabina Pucci
Sabina Pucci
GCGilles Chiocchia
Gilles Chiocchia
In prostate cancer the secreted form of clusterin (sCLU) has been described as an anti-apoptotic protein whose expression is increased after therapeutic intervention, whereas, the nuclear protein form nCLU was reported to have pro-apoptotic properties. In order to provide new therapeutic approaches targeting CLU, we developed a strategy based on exon skipping by using a lentiviral construct to preferentially induce the nuclear spliced form of the protein. The molecular construct was transduced in LNCaP cells for testing the modulation of sensitivity of the transduced cells to pro-apoptotic stress. We showed an increase of nCLU/sCLU expression ratio in the prostate cancer cell line “LNCaP” after lentiviral vector-U7 nCLU transduction. Moreover, we showed a significant inhibition of cell proliferation in nCLU-U7 LNCaP cells after treatment with cisplatin and after exposure to ionizing radiation compared to control cells. Finally, we showed that nCLU-U7 LNCaP cells exposure to UV-C significantly reduced an increase of cell death compared to control. Finally, we showed that modulating nCLU expression had profound impact on Ku70/Bax interaction as well as Rad17 expression which could be a key mechanism in sensitizing cells to cell death. In conclusion, this is the first report showing that increasing of nCLU/sCLU expression ratio by using an “on demand alternative splicing” strategy successfully increased sensitivity to radiotherapy and chemotherapy of prostate cancer cells.

7 November 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SPSabina Pucci
Sabina Pucci
PMP. Mazzarelli
P. Mazzarelli
MZM. J. Zonetti
M. J. Zonetti
TFT. Fisco
T. Fisco
Elena BonannoElena Bonanno
Elena Bonanno
Alessandro MaurielloAlessandro Mauriello
Alessandro Mauriello
Fractalkine is a proinflammatory chemokine that participates in atherosclerotic process mediating the interactions of vascular cells and leukocytes and selective recruitment of Th1 lymphocytes, through interaction with CX3CR1 receptor. The polymorphism of the fractalkine receptor 280M-containing haplotype, which codifies for a receptor with minor expression and with a reduced binding capability, represents a novel protective factor of atherosclerotic disease. We investigated the association among CX3CR1 genotype, the inflammatory infiltrate subpopulations recruited in the plaque, and the in situ expression of fractalkine and its receptor, in patients who died of myocardial infarction (AMI) compared with subjects who died of noncardiac causes. Patients with nonlethal AMI (AMI survivors) were also investigated to correlate the CX3CR1 polymorphisms and the incidence of lethal AMI. A strong T cells infiltrate was found in infarct related artery (IRA) plaques of AMI patients presenting the V249T280haplotype (84%). Conversely, a decreased T cell recruitment was associated with I249T280haplotype in the controls (64%). The significant higher presence of the variant allele I249 in homo- and heterozygosis, found in controls (91%) and in AMI survivors (94%), with respect to the patients who died of AMI (48%), showed the relevance of this polymorphism both in the onset and outcome of acute myocardial infarction. The presence of CX3CR1 polymorphisms could influence the incidence and the outcome of acute myocardial infarction, altering the inflammation of the whole coronary tree by the impaired recruitment of Th1 polarized subpopulation in the coronary plaque.

1 October 2014 in International Journal of Cardiology
Verified
Journal Article
Closed access
SPSabina Pucci
Sabina Pucci
TFT. Fisco
T. Fisco
MZM.J. Zonetti
M.J. Zonetti
Elena BonannoElena Bonanno
Elena Bonanno
PMP. Mazzarelli
P. Mazzarelli
Alessandro MaurielloAlessandro Mauriello
Alessandro Mauriello